Software
-- Achieved 16% revenue growth in the second quarter of fiscal 2008
compared with the second quarter of fiscal 2007.
-- Added 20th PKS customer; new customer is among Pharmaceutical
Executive's Top 50 2007 list.
-- 35% of PKS installed based have purchased additional licenses to date.
-- Achieved second WinNonlin AutoPilot customer.
-- Released four new software products: DMX(R) version 1.6, PKS 3.1 for
Oracle Standard Edition, PKS Validation Suite(TM) 1.1.1, and Trial
Simulator(TM) 2.2.1.
-- Software products now used at more than 360 pharmacy and medical
schools worldwide, supporting more than 3,500 students and teachers.
-- Hosted 4th Annual PKS User Group Meeting in October, where the FDA both
attended and presented.
-- Hosted European software conference that offered PKS case studies in a
collaborative environment to scientific and professional community
attendees.
-- Attained vendor specific objective evidence of fair value (VSOE) for
maintenance and support based on 1-year anniversary of criteria
established in 2006.
Strategic Consulting Services (SCS)
-- Continued to diversify revenue base; two largest clients represented
less than 25% of total SCS revenue in the second fiscal quarter
-- Demonstrated leadership with two key presentations to biopharmaceutical
industry statisticians at the International Biometric Society's annual
ROeS Seminar; Pharsight senior biostatistician and senior scientist
presented.
-- Expanded scientific team with the hiring of three scientists.
-- Sold first license for 1 of 20 available meta-databases to a global
biotechnology company.
Reporting and Analysis Services (RAS)
--
'/>"/>
| SOURCE Pharsight Corporation Copyright©2007 PR Newswire. All rights reserved |